VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of […]
Tag: VAZKEPA
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) — Amarin […]
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top priority on Germany VAZKEPA commercial launch […]
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in April 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) — Amarin […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet